EGF Receptor in Tumor Growth and Progression

1. Front Matter

   Pages I-XIV

   PDF

2. Signal Transduction by EGF Receptor Tyrosine Kinase

   • R. B. Lichtner, R. N. Harkins

   Pages 1-17

3. Characterization of Growth Factor Receptor-Directed Protein Tyrosine Phosphatases

   • F.-D. Böhmer

   Pages 19-44

4. Interaction of Heparin-Binding EGF-Like Growth Factor with Multiple Receptors

   • K. Elenius, G. Allison, S. K. Das, B. C. Paria, S. K. Dey, M. Klagsbrun

   Pages 45-64

5. Epidermal Growth Factor Receptor Expression in Head and Neck Tumorigenesis and Saturation of EGFR with Monoclonal Antibody RG83852

   • D. M. Shin, R. Perez-Soler, W. N. Hittelman, W. K. Hong

   Pages 65-87

6. EGF Receptors as a Target for Therapy and Interactions with Angiogenesis

   • A. L. Harris

   Pages 89-103

7. erbB Signalling and Endocrine Sensitivity of Human Breast Cancer

   • R. I. Nicholson, J. M. W. Gee, H. Jones, M. E. Harper, A. E. Wakeling, P. Willsher et al.

   Pages 105-128

8. The Role of Estrogen in the Regulation of EGFR Expression

   • R. I. Yarden, M. A. Wilson, M. Barth, S. A. Chrysogelos

   Pages 129-154

9. Multifunctional Growth Factors in Tumor Progression

   • F. Radvanyi, S. Bellusci, B. Boyer, J. Jouanneau, P. Savagner, A. M. Vallés et al.

   Pages 155-164

10. The Role of Epidermal Growth Factor Receptor in the Initiation and Progression of Malignancy

    • K. Khazaie

    Pages 165-183

11. Preclinical Studies with Human Tumour Xenografts Using Rat Monoclonal Antibodies Directed Against the Epidermal Growth Factor Receptor

    • S. A. Eccles, H. Modjtahedi, W. Court, J. Titley, G. Box, C. Dean

    Pages 185-209

12. Recombinant Fusion Toxins Targeted to Members of the ErbB Family of Receptor Tyrosine Kinases

    • W. Wels, M. Schmidt, M. Jeschke, B. Groner, R. R. Beerli, N. E. Hynes et al.

    Pages 211-232

13. EGF Receptor Inhibition by Antibody as Anticancer Therapy

    • J. Mendelsohn, J. Baselga, X. Wu, D. Peng, C. Brown, J. L. Chou et al.

    Pages 233-251

14. Back Matter

    Pages 253-258

    PDF

The last 15 years have brought an understanding of growth and differentiation at the molecular level, expanding our knowledge of the origin and progression of cancer. Early breakthroughs defining growth control pathways came via studies of oncogenes, mutated signaling molecules that have lost the capacity to tum off their proliferative signal. Oncogenes with diverse growth-promoting activities have been discovered, covering the gamut from cell surface to nuclear signaling. Sequencing of these oncogenes revealed that they were mutated forms of captured cellular genes and displayed tyrosine kinase activity. The epidermal growth factor (EGF) receptor was the first of 40-50 transmembrane tyrosine kinase receptors to be cloned and sequenced. Beyond cell proliferation, activation of EGF receptor by its specific ligands controls important physiological processes, such as cell differentiation, apoptosis, cell migration, and cell shape. Activation of autocrine growth loops, consisting in solid human tumors of upregulated expression of EGFR together with increased production of ligands suggested its crucial role in autonomous tumor growth.

• EGF Receptor
• EGF Rezeptor
• Signal Transduction
• Signaltransduktion
• Tyrosinkinase
• angiogenesis
• antibody
• breast cancer
• cancer
• cancer therapy
• growth factor
• tumor
• tumor growth
• tumor progression
• tumorigenesis

• Research Laboratories of Schering AG, Experimental Oncology, Berlin, Germany

  R. B. Lichtner

• Berlex Biosciences, Protein Biochemistry and Biophysics, Richmond, USA

  R. N. Harkins

Policies and ethics